Sonoma Pharmaceuticals (SNOA) 10-Q 16 Feb 21 2021 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Dec. 31, 2020	Feb. 11, 2021
Cover [Abstract]
Entity Registrant Name	Sonoma Pharmaceuticals, Inc.
Entity Central Index Key	0001367083
Document Type	10-Q
Document Quarterly Report	true
Amendment Flag	false
Document Period End Date	Dec. 31, 2020
Current Fiscal Year End Date	--03-31
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		2,077,392
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive data current	Yes
Entity File Number	001-33216
Entity Incorporation State Country Code	DE
Entity Shell company	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Dec. 31, 2020	Mar. 31, 2020
Current assets:
Cash and cash equivalents	$ 5,541,000	$ 3,691,000
Accounts receivable, net	4,408,000	4,062,000
Inventories, net	2,958,000	2,192,000
Prepaid expenses and other current assets	3,087,000	2,256,000
Current portion of deferred consideration, net of discount	218,000	182,000
Total current assets	16,212,000	12,383,000
Operating lease right-of-use assets	671,000	963,000
Property and equipment, net	404,000	365,000
Deferred consideration, net of discount, less current portion	829,000	786,000
Other assets	115,000	64,000
Total assets	18,231,000	14,561,000
Current liabilities:
Accounts payable	2,430,000	2,086,000
Accrued expenses and other current liabilities	1,049,000	1,774,000
Deferred revenue	150,000	228,000
Deferred revenue Invekra	54,000	45,000
Operating lease liabilities	200,000	251,000
Current portion of long-term debt	0	481,000
Total current liabilities	3,883,000	4,865,000
Operating lease liabilities - non-current	471,000	746,000
Long-term deferred revenue Invekra	251,000	245,000
Long-term debt	1,310,000	0
Total liabilities	5,915,000	5,856,000
Stockholders' Equity
Convertible preferred stock, $0.0001 par value; 714,286 shares authorized at December 31, 2020 and March 31, 2020, respectively, 0 and 1.55 shares issued and outstanding at December 31, 2020 and March 31, 2020, respectively	0	0
Common stock, $0.0001 par value; 24,000,000 shares authorized at December 31, 2020 and March 31, 2020, 2,079,059 and 1,777,483 shares issued and outstanding at December 31, 2020 and March 31, 2020, respectively	2,000	2,000
Additional paid-in capital	189,085,000	186,559,000
Accumulated deficit	(172,536,000)	(172,246,000)
Accumulated other comprehensive loss	(4,235,000)	(5,610,000)
Total stockholders' equity	12,316,000	8,705,000
Total liabilities and stockholders' equity	$ 18,231,000	$ 14,561,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Dec. 31, 2020	Mar. 31, 2020
Common stock par value	$ .0001	$ 0.0001
Common stock shares authorized	24,000,000	24,000,000
Common stock shares issued	2,079,059	1,777,483
Common stock shares outstanding	2,079,059	1,777,483
Convertible Preferred Stock [Member]
Preferred stock par value	$ 0.0001	$ 0.0001
Preferred stock shares authorized	714,286	714,286
Preferred stock shares issued	0	1.55
Preferred stock shares outstanding	0	1.55

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenues	$ 4,936	$ 4,395	$ 16,472	$ 13,616
Cost of revenues	2,941	2,394	9,719	7,147
Gross profit	1,995	2,001	6,753	6,469
Operating expenses
Research and development	33	248	425	856
Selling, general and administrative	2,100	2,861	6,963	9,779
Total operating expenses	2,133	3,109	7,388	10,635
Loss from operations	(138)	(1,108)	(635)	(4,166)
Interest expense	(5)	(1)	(12)	(13)
Interest income	3	33	14	117
Other (expense) income, net	(490)	(134)	(687)	(234)
Gain on sale of assets	4	0	137	2,472
Loss from continuing operations	(626)	(1,210)	(1,183)	(1,824)
Income (loss) from discontinued operations (Note 4)	(24)	126	893	252
Net loss	$ (650)	$ (1,084)	$ (290)	$ (1,572)
Net income (loss) per share: basic and diluted
Continuing operations	$ (0.31)	$ (0.81)	$ (0.60)	$ (1.32)
Discontinued operations:	(0.01)	0.09	0.45	0.18
Net income (loss) per share: basic and diluted	$ (0.32)	$ (0.72)	$ (0.15)	$ (1.14)
Weighted-average number of shares used in per common share calculations: basic and diluted	2,052	1,500	1,967	1,378
Other comprehensive income (loss)
Net loss	$ (650)	$ (1,084)	$ (290)	$ (1,572)
Foreign currency translation adjustments	1,020	264	1,375	168
Comprehensive income (loss)	$ 370	$ (820)	$ 1,085	$ (1,404)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities
Net loss	$ (290)	$ (1,572)
Adjustments to reconcile net loss to net cash (used in) operating activities:
Depreciation and amortization	187	212
Stock-based compensation	316	537
Gain on sale of assets	(770)	0
Changes in operating assets and liabilities:
Accounts receivable	464	(1,506)
Inventories	(403)	630
Deferred consideration	110	0
Prepaid expenses and other current assets	(413)	(214)
Operating lease right-of-use assets	306	384
Accounts payable	(168)	884
Accrued expenses and other current liabilities	(779)	(86)
Operating lease liabilities	(343)	(402)
Deferred revenue	(119)	133
Net cash used in operating activities	(1,902)	(1,000)
Cash flows from investing activities:
Purchases of property and equipment	(174)	(86)
Deposits	(44)	50
Proceeds from sale of assets	610	0
Net cash provided by (used in) investing activities	392	(36)
Cash flows from financing activities:
Proceeds from exercise of stock options and warrants	2,210	1,376
Proceeds from new debt	1,310	0
Principal payments on capital leases	0	(13)
Principal payments on long-term debt	(481)	(334)
Net cash provided by financing activities	3,039	1,029
Effect of exchange rate on cash and cash equivalents	321	45
Net increase in cash and cash equivalents	1,850	38
Cash and cash equivalents, beginning of period	3,691	3,689
Cash and cash equivalents, end of period	5,541	3,727
Supplemental disclosure of cash flow information:
Cash paid for interest	$ 12	$ 1

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Series C Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total
Beginning balance, shares at Mar. 31, 2019	2	1,316,335
Beginning balance, value at Mar. 31, 2019		$ 2	$ 184,074	$ (169,238)	$ (4,349)	$ 10,489
Cumulative effect related to April 1, 2019 adoption of Accounting Standards Update (ASU) 2016-02, Leases (Topic 842)				(59)		(59)
Stock based compensation related to common stock restricted stock grants, shares		835
Stock based compensation related to common stock restricted stock grants, value			20			20
Stock-based compensation expense, net of forfeitures			272			272
Foreign currency translation adjustment					67	67
Net income (loss)				715		715
Ending balance, shares at Jun. 30, 2019	2	1,317,170
Ending balance, value at Jun. 30, 2019		$ 2	184,366	(168,582)	(4,282)	11,504
Stock based compensation related to common stock restricted stock grants, shares		834
Stock based compensation related to common stock restricted stock grants, value			9			9
Stock-based compensation expense, net of forfeitures			124			124
Foreign currency translation adjustment					(163)	(163)
Net income (loss)				(1,203)		(1,203)
Ending balance, shares at Sep. 30, 2019	2	1,318,004
Ending balance, value at Sep. 30, 2019		$ 2	184,499	(169,785)	(4,445)	10,271
Stock based compensation related to common stock restricted stock grants, shares		346
Stock based compensation related to common stock restricted stock grants, value			6			6
Stock-based compensation expense, net of forfeitures			106			106
Foreign currency translation adjustment					264	264
Common stock issued in connection with November 29, 2019 registered direct offering, shares		446,577
Common stock issued in connection with November 29, 2019 registered direct offering, value			1,376			1,376
Net income (loss)				(1,084)		(1,084)
Ending balance, shares at Dec. 31, 2019	2	1,777,483
Ending balance, value at Dec. 31, 2019		$ 2	186,257	(170,869)	(4,181)	11,209
Beginning balance, shares at Mar. 31, 2020	2	1,777,483
Beginning balance, value at Mar. 31, 2020		$ 2	186,559	(172,246)	(5,610)	8,705
Stock based compensation related to common stock restricted stock grants, shares		3,086
Stock based compensation related to common stock restricted stock grants, value			18			18
Stock-based compensation expense, net of forfeitures			45			45
Foreign currency translation adjustment					167	167
Issuance of common stock due to warrant exercises, shares		169,167
Issuance of common stock due to warrant exercises, value			1,490			1,490
Conversion of Series C convertible preferred stock into common stock, shares	2	17,222
Conversion of Series C convertible preferred stock into common stock, value
Net income (loss)				240		240
Ending balance, shares at Jun. 30, 2020		1,966,958
Ending balance, value at Jun. 30, 2020		$ 2	188,112	(172,006)	(5,443)	10,665
Beginning balance, shares at Mar. 31, 2020	2	1,777,483
Beginning balance, value at Mar. 31, 2020		$ 2	186,559	(172,246)	(5,610)	8,705
Ending balance, shares at Dec. 31, 2020		2,079,059
Ending balance, value at Dec. 31, 2020		$ 2	189,085	(172,536)	(4,235)	12,316
Beginning balance, shares at Jun. 30, 2020		1,966,958
Beginning balance, value at Jun. 30, 2020		$ 2	188,112	(172,006)	(5,443)	10,665
Stock-based compensation expense, net of forfeitures			160			160
Foreign currency translation adjustment					188	188
Issuance of common stock due to options exercises, shares		74,451
Issuance of common stock due to options exercises, value			429			429
Net income (loss)				120		120
Ending balance, shares at Sep. 30, 2020		2,041,409
Ending balance, value at Sep. 30, 2020		$ 2	188,701	(171,886)	(5,255)	11,562
Stock based compensation related to common stock restricted stock grants, shares		833
Stock based compensation related to common stock restricted stock grants, value			3			3
Foreign currency translation adjustment					1,020	1,020
Issuance of common stock due to warrant exercises, shares		31,817
Issuance of common stock due to warrant exercises, value			269			269
Issuance of common stock due to options exercises, shares		5,000
Issuance of common stock due to options exercises, value			22			22
Stock based compensation related to common stock options			90			90
Net income (loss)				(650)		(650)
Ending balance, shares at Dec. 31, 2020		2,079,059
Ending balance, value at Dec. 31, 2020		$ 2	$ 189,085	$ (172,536)	$ (4,235)	$ 12,316

1. Organization and Recent Deve

1. Organization and Recent Developments	9 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Recent Developments	Note 1. Organization and Recent Developments Organization Sonoma Pharmaceuticals, Inc. (the “Company”) was incorporated under the laws of the State of California in April 1999 and was reincorporated under the laws of the State of Delaware in December 2006. The Company’s principal office was moved to Woodstock, Georgia from Petaluma, California in June 2020. The Company is a global healthcare leader for developing and producing stabilized hypochlorous acid (“HOCl”) products for a wide range of applications, including wound care, animal health care, eye care, oral care, nasal care and dermatological conditions. The Company’s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of HOCl show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. The Company’s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The Company sells its products either directly or via partners in 54 countries worldwide. Impact of Coronavirus The spread of the coronavirus (“COVID-19”) has affected many segments of the global economy, including the pharmaceutical industry. The COVID-19 outbreak, which the World Health Organization has classified as a pandemic, has prompted governments and regulatory bodies throughout the world to enact broad precautionary measures, including “stay-at-home” orders, restrictions on the performance of “non-essential” services, public gatherings and travel. Health systems, including key markets where the Company operates, have been, or may be, overwhelmed with high volumes of patients suffering from COVID-19. The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, access to capital markets, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of December 31, 2020 and through the date of the filing of this Quarterly Report on Form 10-Q. The accounting matters assessed included, but were not limited to, the Company’s allowance for doubtful accounts and credit losses, inventory obsolescence, and supplier agreements. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in additional material impacts to the Company’s consolidated financial statements in future reporting periods. Despite the Company’s efforts, the ultimate impact of COVID-19 depends on factors beyond the Company’s knowledge or control, including the duration and severity of the outbreak, as well as third-party actions taken to contain its spread and mitigate its public health effects. As a result, the Company is unable to estimate the extent to which COVID-19 will negatively impact its financial results or liquidity. Reverse Stock Split Effective June 19, 2019, the Company effected a reverse stock split of its common stock, par value $0.0001 per share. Every nine shares of common stock were reclassified and combined into one share of common stock. No fractional shares were issued as a result of the reverse stock split. Instead, each resulting fractional share of common stock was down to one whole share and each fractional share settled with cash. The reverse stock split reduced the number of shares of the Company’s common stock outstanding from 11,972,328 to 1,328,891. The total number of authorized shares of common stock was not proportionally decreased and the par value per share of the common stock continues to be $0.0001. All common shares and per share amounts contained in the condensed consolidated financial statements and accompanying footnotes have been retroactively adjusted to reflect a 1-for-9 reverse stock split. Basis of Presentation The accompanying unaudited condensed consolidated financial statements as of December 31, 2020 and for the three and nine months then ended have been prepared in accordance with the accounting principles generally accepted in the United States of America for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. The condensed consolidated balance sheet as of December 31, 2020, the condensed consolidated statements of comprehensive income (loss) for the three and nine months ended December 31, 2020 and 2019, the cash flows for the nine months ended December 31, 2020 and 2019 and the condensed consolidated statement of stockholders’ equity for the three and nine months ended December 31, 2020 and 2019 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the consolidated financial position, operating results and cash flows for the periods presented. The results for the three and nine months ended December 31, 2020 are not necessarily indicative of results to be expected for the year ending March 31, 2021 or for any future interim period. The condensed consolidated balance sheet at March 31, 2020 has been derived from audited consolidated financial statements. These unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended March 31, 2020, and notes thereto included in the Company’s annual report on Form 10-K, which was filed with the SEC on July 10, 2020.

2. Liquidity and Financial Cond

2. Liquidity and Financial Condition	9 Months Ended
	Dec. 31, 2020
Liquidity And Financial Condition
Liquidity and Financial Condition	Note 2. Liquidity and Financial Condition The Company reported a net loss of $650,000 and $290,000 for the three and nine months ended December 31, 2020. At December 31, 2020 and March 31, 2020, the Company’s accumulated deficit amounted to $172,536,000 and $172,246,000, respectively. The Company had working capital of $12,329,000 and $7,518,000 as of December 31, 2020 and March 31, 2020, respectively. On June 24, 2020, the Company closed on an asset purchase agreement for the sale of its Micromed Laboratories division and testing facility, including all of Micromed’s assets, such as testing equipment, certain office furniture and customer list, with Infinity Labs SD Inc. for an aggregate purchase price of $850,000. On the closing date, the Company received $610,000 in cash from this sale which was adjusted for working capital, a credit of $100,000 for future testing services from Infinity over the next two years in lieu of cash, and $60,000 held in escrow for one year, subject to adjustment for certain indemnity claims or purchase price adjustments. The Company also retained its accounts receivables outstanding on the date of closing in the amount of approximately $81,000 and an insignificant amount of liabilities. As part of the transaction, Infinity also assumed the Petaluma lease for the office and lab space. The Company retained the warehouse space to store inventory and assets until September 30, 2020. On May 1, 2020, the Company received loan proceeds in the amount of $1,310,000 under the Paycheck Protection Program (“PPP”), from Coastal States Bank in Atlanta, Georgia. The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act, “CARES Act”, provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued interest are forgivable after eight or 24 weeks as long as the Company uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains payroll levels. The amount of loan forgiveness will be reduced if the Company terminated employees or reduced salaries during the applicable period. The unsecured loan, which is in the form of a note dated April 29, 2020, matures on April 29, 2022 and bears interest at a rate of 1% per annum, payable monthly commencing on May 1, 2021. The note may be prepaid at any time prior to maturity with no prepayment penalties. The Company has used the loan amount for eligible purposes, such as payroll expenses. The Company currently believes that its use of the loan proceeds will meet the conditions for $930,000 in forgiveness of the loan. During the nine months ended December 31, 2020, the Company received proceeds of $451,000 from the exercise of stock options by employees and consultants. During the nine months ended December 31, 2020, the Company received proceeds of $1,759,000 from the exercise of November 2018 common stock purchase warrants by several investors. Management believes that the Company has access to additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means; however, the Company cannot provide any assurance that other new financings will be available on commercially acceptable terms, if needed. If the economic climate in the U.S. deteriorates, the Company’s ability to raise additional capital could be negatively impacted. If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays in the Company’s continued efforts to commercialize its products, which is critical to the realization of its business plan and the future operations of the Company. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.

3. Summary of Significant Accou

3. Summary of Significant Accounting Policies	9 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3. Summary of Significant Accounting Policies Reclassification Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on the previously reported net loss. Use of Estimates The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include reserves and write-downs related to receivables and inventories, the recoverability of long-lived assets, the valuation allowance relating to the Company’s deferred tax assets, valuation of equity and derivative instruments, fair value allocation of assets sold to Invekra, Petagon, Microsafe and the estimated amortization periods of upfront product licensing fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly. Net Income (Loss) per Share The Company computes basic net income (loss) per share by dividing net income per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. Three Months Ended December 31, Nine Months Ended December 31, (In thousands, except per share data) 2020 2019 2020 2019 Numerator: Loss from continuing operations $ (626 ) $ (1,210 ) $ (1,183 ) $ (1,824 ) Income (loss) from discontinued operations (24 ) 126 893 252 Net loss $ (650 ) $ (1,084 ) $ (290 ) $ (1,572 ) Denominator: Weighted-average number of common shares outstanding: basic and diluted 2,052 1,500 1,967 1,378 Loss per share from continuing operations $ (0.31 ) $ (0.81 ) $ (0.60 ) $ (1.32 ) Income (loss) per share from discontinued operations (0.01 ) 0.09 0.45 0.18 Net loss per share: basic and diluted $ (0.32 ) $ (0.72 ) $ (0.15 ) $ (1.14 ) The computation of basic loss per share for the three and nine months ended December 31, 2020 and 2019 excludes the potentially dilutive securities summarized in the table below because their inclusion would be anti-dilutive. Three Months Ended December 31, Nine Months Ended December 31, (In thousands) 2020 2019 2020 2019 Stock options 61 358 70 358 Restricted stock 1 2 1 2 Series C – 17 – 17 Warrants 119 468 119 468 Common stock units (1) 46 46 46 46 227 891 236 891 (1) Consists of 30,668 restricted stock units and warrants to purchase 15,332 shares of common stock Revenue Recognition Revenue is recognized when the entity transfers promised goods or services to the customer, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under the agreement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. The Company derives the majority of its revenue from its distributor relationships. The Company also sells products to a customer base including hospitals, medical centers, doctors, pharmacies, wholesalers and directly to end users. The Company also has entered into agreements to license its technology and products. The Company considers customer purchase orders, which in some cases are governed by master sales agreements, to be the contracts with a customer. For each contract, the Company considers the promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction price, the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects to be entitled. For all of its sales to non-consignment distribution channels, revenue is recognized when control of the product is transferred to the customer (i.e. when its performance obligation is satisfied), which typically occurs when title passes to the customer upon shipment but could occur when the customer receives the product based on the terms of the agreement with the customer. For product sales to its value-added resellers, non-stocking distributors and end-user customers, the Company grants return privileges to its customers. The Company has a long history with its customers and is able to estimate the amount of product that will be returned. Sales incentives and other programs that the Company may make available to these customers are considered to be a form of variable consideration and the Company maintains estimated accruals and allowances using the expected value method. The Company has entered into consignment arrangements in which goods are left in the possession of another party to sell. As products are sold from the customer to third parties, the Company recognizes revenue based on a variable percentage of a fixed price. Revenue recognized varies based on if a patient is covered by insurance or is not covered by insurance. In addition, the Company may incur a revenue deduction related to the use of the Company’s rebate program. Sales to stocking distributors are made under terms with fixed pricing and limited rights of return (known as “stock rotation”) of the Company’s products held in their inventory. Revenue from sales to distributors is recognized upon the transfer of control to the distributor. The Company assessed the promised goods and services in the technical support to Invekra for a ten-year period as being a distinct service that Invekra can benefit from on its own and is separately identifiable from any other promises within the contract. Given that the distinct service is not substantially the same as other goods and services within the Invekra contract, the Company accounted for the distinct service as a performance obligation. Disaggregation of Revenue The following table presents the Company’s disaggregated revenues by revenue source: (In thousands) Three Months Ended December 31, Nine Months Ended December 31, Product 2020 2019 2020 2019 Human Care $ 3,534 $ 3,528 $ 13,628 $ 11,290 Animal Care 1,357 853 2,745 2,188 Other 45 14 99 138 $ 4,936 $ 4,395 $ 16,472 $ 13,616 Accounts Receivable Trade accounts receivable are recorded net of allowances for cash discounts for prompt payment, doubtful accounts, and sales returns. Estimates for cash discounts and sales returns are based on analysis of contractual terms and historical trends. The Company’s policy is to reserve for uncollectible accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance for doubtful accounts is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Other factors that the Company considers include its existing contractual obligations, historical payment patterns of its customers and individual customer circumstances, an analysis of days sales outstanding by customer and geographic region, and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Account balances deemed to be uncollectible are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The allowance for doubtful accounts represents probable credit losses of $35,000 and $1,028,000 at December 31, 2020 and March 31, 2020, respectively. Additionally, at December 31, 2020 and March 31, 2020 the Company has allowances of $2,938,000 and $1,230,000, respectively, related to potential discounts, returns, distributor fees and rebates. The allowances are included in Accounts Receivable, net in the accompanying condensed consolidated balance sheets. Inventories Inventories are stated at the lower of cost, cost being determined on a standard cost basis (which approximates actual cost on a first-in, first-out basis), or net realizable value. Due to changing market conditions, estimated future requirements, age of the inventories on hand and production of new products, the Company regularly reviews inventory quantities on hand and records a provision to write down excess and obsolete inventory to its estimated net realizable value. The Company recorded a provision to reduce the carrying amounts of inventories to their net realizable value in the amount of $269,000 and $600,000 at December 31, 2020 and March 31, 2020, respectively, which is included in cost of product revenues on the Company’s accompanying condensed consolidated statements of comprehensive income (loss). Subsequent Events Management has evaluated subsequent events or transactions occurring through the date the condensed consolidated financial statements were issued. (See Note 13) Accounting Pronouncements Pending Adoption In December 2019, the FASB issued ASU No. 2019-12, Income Taxes: Simplifying the Accounting for Income Taxes (“Topic 740”), which simplifies the accounting for income taxes, eliminates certain exceptions within Topic 740 and clarifies certain other aspects of the current guidance to promote consistency among reporting entities. The new standard is effective for fiscal years beginning after December 15, 2020 on a prospective basis and early adoption is permitted. The Company is currently evaluating the impact of the provisions of this standard on its Consolidated Financial Statements. Recent Accounting Standards Accounting standards that have been issued or proposed by the FASB, the SEC or other standard setting bodies that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption.

4. Discontinued Operations_ Sal

4. Discontinued Operations: Sale of Assets to Infinity Labs SD, Inc.	9 Months Ended
	Dec. 31, 2020
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations: Sale of Assets to Infinity Labs SD, Inc.	Note 4. Discontinued Operations: Sale of Assets to Infinity Labs SD, Inc. On June 24, 2020, the Company closed on an asset purchase agreement for the sale of its Micromed Laboratories division and testing facility, including all of Micromed’s assets, such as testing equipment, certain office furniture and customer list, with Infinity Labs SD Inc. (“Infinity”) for an aggregate purchase price of $850,000. On the closing date, the Company received $610,000 in cash from this sale which was adjusted for working capital, a credit of $100,000 for future testing services from Infinity over the next two years in lieu of cash, and $60,000 held in escrow for one year, subject to adjustment for certain indemnity claims or purchase price adjustments. The Company also retained its accounts receivables outstanding on the date of closing in the amount of approximately $81,000 and an insignificant amount of liabilities. As part of the transaction, Infinity also assumed the Petaluma lease for the office and lab space. The Company retained the warehouse space to store inventory and assets until September 30, 2020. Accounting for the disposition For accounting purposes, the Company determined that there was only one discrete component of the sale to Infinity. This component was the customer base and related services to be provided. Component of Sale Methodology to Estimate Selling Price Customer Base Based upon revenues expected from a market participant to provide technical services at expected service levels The Company determined an arm’s length selling price for each component of the sale and then allocated the net proceeds received to the components on a relative selling price basis. The Company estimated the selling prices of each component as described below: Proceeds were allocated to the components of the sale based upon their relative selling prices are as follows: Customer base $ 850,000 Less: Funds remaining in escrow (60,000 ) Less: Services due from buyer (100,000 ) Less: Working capital adjustment (80,000 ) Total proceeds $ 610,000 Discontinued operations As of June 24, 2020, the Company determined that the sale of its Micromed division to Infinity qualified as a sale of a component of its business and, as such, all such activity prior to consummation of the sale is required to be included in discontinued operations on the Company’s statement of operations. The carrying value of the assets and liabilities of discontinued operations on the condensed consolidated balance sheets as of December 31, 2020 and March 31, 2020 were as follows: December 31, 2020 March 31, 2020 Assets Accounts receivable (net) $ – $ 89,000 Inventory – 11,000 Operating lease, right of use – 604,000 Total current assets of discontinued operations $ – $ 704,000 Liabilities Accounts payable $ – $ 18,000 Operating lease – 117,000 Total current liabilities of discontinued operations $ – $ 135,000 Operating lease $ – $ 511,000 Total Long-term liabilities of discontinued operations $ – $ 511,000 The operations of the Micromed business included in discontinued operations is summarized as follows: Three Months Ended December 31, Nine Months Ended December 31, 2020 2019 2020 2019 Revenues $ – $ 283,000 $ 214,000 $ 741,000 Cost of revenues – 126,000 53,000 391,000 Selling general and administrative expenses (1,000 ) 31,000 38,000 98,000 Income (loss) from discontinued operations before tax 1,000 126,000 123,000 252,000 Gain (loss) on disposal of discontinued operations before income taxes (25,000 ) – 770,000 – Total income (loss) from discontinued operations, before tax (24,000 ) 126,000 893,000 252,000 Income Tax benefit (expense) – – – – Income (loss) from discontinued operations, net of tax $ (24,000 ) $ 126,000 $ 893,000 $ 252,000

5. Condensed Consolidated Balan

5. Condensed Consolidated Balance Sheets	9 Months Ended
	Dec. 31, 2020
Disclosure Text Block Supplement [Abstract]
Condensed Consolidated Balance Sheets	Note 5. Condensed Consolidated Balance Sheets Inventories, net Inventories, net consist of the following: December 31, March 31, 2020 2020 Raw materials $ 1,843,000 $ 1,128,000 Finished goods 1,115,000 1,064,000 $ 2,958,000 $ 2,192,000 The Company reserved $269,000 and $600,000 for obsolescence at December 31, 2020 and March 31, 2020, respectively. Leases The Company's operating leases are comprised primarily of operating facility leases. The Company did not have any finance leases as of December 31, 2020 and March 31, 2020. Balance sheet information related to our leases is presented below: December 31, March 31, 2020 2020 Operating leases: Operating lease right-of-use assets $ 671,000 $ 963,000 Operating lease liabilities – current 200,000 251,000 Operating lease liabilities – non-current 471,000 746,000 Other information related to operating leases is presented below: As of December 31, 2020, the annual minimum lease payments of our operating lease liabilities were as follows: Three Months Ended December 31, Nine Months Ended December 31, 2020 2019 2020 2019 Operating Lease Costs $ 61,000 $ 146,000 $ 230,000 $ 444,000 Operating cash flows from operating leases 306,000 384,000 For Years Ending March 31, 2021 (excluding the nine months ended December 31, 2020) $ 56,000 2022 226,000 2023 183,000 2024 150,000 2025 104,000 Thereafter – Total future minimum lease payments, undiscounted 719,000 Less: imputed interest (48,000 ) Present value of future minimum lease payments $ 671,000 Weighted-average remaining lease term – operating leases (in months) 41 Weighted-average discount rate – operating leases 6.00%

6. Commitments and Contingencie

6. Commitments and Contingencies	9 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6. Commitments and Contingencies Legal Matters The Company may be involved in legal matters arising in the ordinary course of business including matters involving proprietary technology. While management believes that such matters are currently insignificant, matters arising in the ordinary course of business for which the Company is or could become involved in litigation may have a material adverse effect on its business and financial condition of comprehensive loss. Employment Agreements As of December 31, 2020, the Company had employment agreements in place with two of its key executives. One of the agreements provides, among other things, for the payment of up to twelve months of severance compensation for terminations under certain circumstances. At December 31, 2020, potential severance payments to key executives would be $250,000, if triggered. Related Party Transactions Effective September 25, 2019, Ms. Trombly was appointed the Chief Executive Officer of the Company. Ms. Trombly is the owner of Trombly Business Law, PC which has been retained by the Company to advise on certain corporate and securities law matters. During the three and nine months ended December 31, 2020, the Company incurred $51,000 and $165,000, respectively in legal services from Trombly Business Law, PC. During the three and nine months ended December 31, 2019, the Company incurred $84,000 and $220,000 in legal services from Trombly Business Law, PC, respectively.

7. Debt

7. Debt	9 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Debt	Note 7. Debt On May 1, 2020, the Company received loan proceeds in the amount of $1,310,000 under the Paycheck Protection Program (“PPP”), from Coastal States Bank in Atlanta, Georgia. The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act, “CARES Act”, provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued interest are forgivable after eight or 24 weeks as long as the Company uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains payroll levels. The amount of loan forgiveness will be reduced if the Company terminated employees or reduced salaries during the applicable period. The unsecured loan, which is in the form of a note dated April 29, 2020, matures on April 29, 2022 and bears interest at a rate of 1% per annum, payable monthly commencing on May 1, 2021. The note may be prepaid at any time prior to maturity with no prepayment penalties. The Company used the loan amount for eligible purposes, such as payroll expenses. While the Company currently believes that its use of the loan proceeds will meet the conditions for forgiveness of the loan, it cannot assure that it will be eligible for forgiveness, in whole or in part. The Company currently believes that its use of the loan proceeds will meet the conditions for $930,000 in forgiveness of the loan.

8. Stockholders' Equity

8. Stockholders' Equity	9 Months Ended
	Dec. 31, 2020
Stockholders' Equity
Stockholders' Equity	Note 8. Stockholders’ Equity Authorized Capital The Company is authorized to issue up to 24,000,000 shares of common stock with a par value of $0.0001 per share and 714,286 shares of convertible preferred stock with a par value of $0.0001 per share.

9. Stock-Based Compensation

9. Stock-Based Compensation	9 Months Ended
	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Stock-Based Compensation	Note 9. Stock-Based Compensation Stock-based compensation expense is as follows: Three Months Ended December 31, Nine Months Ended December 31, (In thousands) 2020 2019 2020 2019 Cost of revenues $ – $ 17 $ (27 ) $ 51 Research and development – 19 26 60 Selling, general and administrative 93 76 317 426 Total stock-based compensation $ 93 $ 112 $ 316 $ 537 At December 31, 2020, there were unrecognized compensation costs of $2,007 related to stock options which is expected to be recognized over a weighted-average amortization period of 0.24 years. At December 31, 2020, there were unrecognized compensation costs of $8,168 related to restricted stock which is expected to be recognized over a weighted-average amortization period of 0.72 years. Stock options award activity is as follows: Number of Weighted- Weighted- Aggregate Outstanding at April 1, 2020 378,000 $ 26.55 – – Options granted – $ – – – Options exercised 79,451 $ 5.68 – $ 285,326 Options forfeited 113,798 $ 6.05 – – Options expired 23,866 $ 123.02 – – Outstanding at December 31, 2020 160,885 $ 37.03 7.47 $ 291,291 Exercisable at December 31, 2020 156,575 $ 37.74 7.44 $ 281,616 The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company’s common stock, or $7.26 per share at December 31, 2020. Restricted stock award activity is as follows: Number of Shares Weighted Average Award Date Fair Value per Share Unvested restricted stock awards outstanding at April 1, 2020 1,666 $ 13.68 Restricted stock awards granted 5,695 4.79 Restricted stock awards vested (6,528 ) 5.92 Restricted stock awards forfeited – – Unvested restricted stock awards outstanding at December 31, 2020 833 $ 13.68 The Company did not capitalize any cost associated with stock-based compensation. The Company issues new shares of common stock upon exercise of stock options or release of restricted stock awards. The Company issues new shares of common stock upon exercise of stock-based awards. No income tax benefit has been recognized relating to stock-based compensation expense and no tax benefits have been realized from exercised stock options.

10. Income Taxes

10. Income Taxes	9 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Note 10. Income Taxes The Company only recognizes tax benefits from an uncertain tax position if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. To date, the Company has not recognized such tax benefits in its consolidated financial statements. On March 27, 2020 Congress approved and the President signed the CARES Act. The CARES Act is an emergency economic stimulus package in response to the COVID-19 pandemic, which among other things contains numerous tax provisions. The Company considered the various potential income tax provisions and deemed there were no material impacts to its income tax provision at December 31, 2020. The Company does not have any tax positions for which it is reasonably possible the total amount of gross unrecognized tax benefits will increase or decrease within twelve months of March 31, 2020. The unrecognized tax benefits may increase or change during the next year for items that arise in the ordinary course of business.

11. Segment and Geographic Info

11. Segment and Geographic Information	9 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Segment and Geographic Information	Note 11. Segment and Geographic Information The Company generates revenues from products which are sold into the human and animal health care markets. The following table shows the Company’s revenues by geographic region: Three Months Ended December 31, Nine Months Ended December 31, (In thousands) 2020 2019 2020 2019 United States $ 1,978 $ 2,059 $ 5,582 $ 6,753 Latin America 1,307 1,002 5,659 2,715 Europe and Rest of the World 1,651 1,334 5,231 4,148 Total $ 4,936 $ 4,395 $ 16,472 $ 13,616

12. Significant Customer Concen

12. Significant Customer Concentrations	9 Months Ended
	Dec. 31, 2020
Risks and Uncertainties [Abstract]
Significant Customer Concentrations	Note 12. Significant Customer Concentrations For the three months ended December 31, 2020, one customer represented 26% and, another customer represented 24% of net revenue. For the nine months ended December 31, 2020, one customer represented 34% of net revenue and, another customer represented 14% of net revenue. For the three months ended December 31, 2019, one customer represented 21% of net revenue and one customer represented 15% of net revenue. For the nine months ended December 31, 2019, one customer represented 18% of net revenue and one customer represented 12% of net revenue. At December 31, 2020 one customer represented more than 10% of the net accounts receivable balance. At March 31, 2020, no customer represented more than 10% of the net accounts receivable balance.

13. Subsequent Events

13. Subsequent Events	9 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	Note 13. Subsequent Events Option Grants On January 7, 2021, the Company awarded stock options to certain executive officers of the Company. The grant was part of the annual company-wide grant to all employees in recognition of their services. The exercise price of the options is based on the closing price of our common stock of $8.03 per share on January 7, 2021, and the options vest in three equal tranches on the first, second and third anniversary of the grant date. All options vest upon change of control. Any unvested options will expire if the employment of the respective executive terminates prior to the vesting date. The option grants are as follows: • Amy Trombly, Chief Executive Officer: 27,777 options • Jerry Dvonch, Chief Financial Officer: 27,777 options • Bruce Thornton, Chief Operations Officer: 27,777 options Addendum to Employment Agreement with our Chief Executive Officer. On January 4, 2021, the Company entered into an addendum to the employment agreement with the Company’s Chief Executive Officer, Amy Trombly, after her prior agreement expired on December 31, 2020 pursuant to its terms. The parties agreed to extend the term of the employment agreement until March 31, 2021 to sync up the term of the employment agreement to the fiscal year. The addendum adds termination provisions for cause and change of control similar to other Company agreements. In the event Ms. Trombly is terminated without cause or for change in control, she is entitled to: • a lump sum severance payment equal to six months her base salary for termination without cause or one time her base salary for termination upon change of control; • automatic vesting of all unvested time-based options and equity awards; • vesting of performance-based equity compensation awards in accordance with the terms of the awards, if the performance goals are satisfied, such determination to be in the sole discretion of the Compensation Committee or the Board, as the case may be; and • reimbursement for health care premiums under COBRA until the earliest of: (i) one year following the date of termination; (ii) the date she is no longer eligible to receive COBRA continuation coverage; or (iii) until she becomes eligible for medical insurance coverage provided by another employer. In case of termination without cause, Ms. Trombly may also be awarded a bonus, upon determination by the Corporation’s Board of Directors or Compensation Committee, as appropriate, to be made in its sole discretion as to whether to grant a bonus, and if such bonus is granted, the amount, form and payment schedule. For the avoidance of doubt, Ms. Trombly shall not be entitled to any bonus solely for reason of termination, unless the Board of Directors or the Compensation Committee, as appropriate, in its sole discretion awards such bonus. In addition, Ms. Trombly is not entitled to certain benefits if she did not comply with the non-competition or the confidentiality provisions of the employment agreement, whether during or after the terms of her employment. Furthermore, the Company is under no obligation to pay the above-mentioned benefits if Ms. Trombly does not comply with the non-solicitation provisions of the employment agreement, which prohibit a terminated executive from interfering with the business relations of the Company or any of its affiliates and from soliciting employees of the Company. These provisions apply during the term of employment and for two years following termination.

3. Summary of Significant Acc_2

3. Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Reclassification	Reclassification Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on the previously reported net loss.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include reserves and write-downs related to receivables and inventories, the recoverability of long-lived assets, the valuation allowance relating to the Company’s deferred tax assets, valuation of equity and derivative instruments, fair value allocation of assets sold to Invekra, Petagon, Microsafe and the estimated amortization periods of upfront product licensing fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly.
Net Income (Loss) per Share	Net Income (Loss) per Share The Company computes basic net income (loss) per share by dividing net income per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. Three Months Ended December 31, Nine Months Ended December 31, (In thousands, except per share data) 2020 2019 2020 2019 Numerator: Loss from continuing operations $ (626 ) $ (1,210 ) $ (1,183 ) $ (1,824 ) Income (loss) from discontinued operations (24 ) 126 893 252 Net loss $ (650 ) $ (1,084 ) $ (290 ) $ (1,572 ) Denominator: Weighted-average number of common shares outstanding: basic and diluted 2,052 1,500 1,967 1,378 Loss per share from continuing operations $ (0.31 ) $ (0.81 ) $ (0.60 ) $ (1.32 ) Income (loss) per share from discontinued operations (0.01 ) 0.09 0.45 0.18 Net loss per share: basic and diluted $ (0.32 ) $ (0.72 ) $ (0.15 ) $ (1.14 ) The computation of basic loss per share for the three and nine months ended December 31, 2020 and 2019 excludes the potentially dilutive securities summarized in the table below because their inclusion would be anti-dilutive. Three Months Ended December 31, Nine Months Ended December 31, (In thousands) 2020 2019 2020 2019 Stock options 61 358 70 358 Restricted stock 1 2 1 2 Series C – 17 – 17 Warrants 119 468 119 468 Common stock units (1) 46 46 46 46 227 891 236 891 (1) Consists of 30,668 restricted stock units and warrants to purchase 15,332 shares of common stock
Revenue Recognition	Revenue Recognition Revenue is recognized when the entity transfers promised goods or services to the customer, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under the agreement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. The Company derives the majority of its revenue from its distributor relationships. The Company also sells products to a customer base including hospitals, medical centers, doctors, pharmacies, wholesalers and directly to end users. The Company also has entered into agreements to license its technology and products. The Company considers customer purchase orders, which in some cases are governed by master sales agreements, to be the contracts with a customer. For each contract, the Company considers the promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction price, the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects to be entitled. For all of its sales to non-consignment distribution channels, revenue is recognized when control of the product is transferred to the customer (i.e. when its performance obligation is satisfied), which typically occurs when title passes to the customer upon shipment but could occur when the customer receives the product based on the terms of the agreement with the customer. For product sales to its value-added resellers, non-stocking distributors and end-user customers, the Company grants return privileges to its customers. The Company has a long history with its customers and is able to estimate the amount of product that will be returned. Sales incentives and other programs that the Company may make available to these customers are considered to be a form of variable consideration and the Company maintains estimated accruals and allowances using the expected value method. The Company has entered into consignment arrangements in which goods are left in the possession of another party to sell. As products are sold from the customer to third parties, the Company recognizes revenue based on a variable percentage of a fixed price. Revenue recognized varies based on if a patient is covered by insurance or is not covered by insurance. In addition, the Company may incur a revenue deduction related to the use of the Company’s rebate program. Sales to stocking distributors are made under terms with fixed pricing and limited rights of return (known as “stock rotation”) of the Company’s products held in their inventory. Revenue from sales to distributors is recognized upon the transfer of control to the distributor. The Company assessed the promised goods and services in the technical support to Invekra for a ten-year period as being a distinct service that Invekra can benefit from on its own and is separately identifiable from any other promises within the contract. Given that the distinct service is not substantially the same as other goods and services within the Invekra contract, the Company accounted for the distinct service as a performance obligation. Disaggregation of Revenue The following table presents the Company’s disaggregated revenues by revenue source: (In thousands) Three Months Ended December 31, Nine Months Ended December 31, Product 2020 2019 2020 2019 Human Care $ 3,534 $ 3,528 $ 13,628 $ 11,290 Animal Care 1,357 853 2,745 2,188 Other 45 14 99 138 $ 4,936 $ 4,395 $ 16,472 $ 13,616
Accounts Receivable	Accounts Receivable Trade accounts receivable are recorded net of allowances for cash discounts for prompt payment, doubtful accounts, and sales returns. Estimates for cash discounts and sales returns are based on analysis of contractual terms and historical trends. The Company’s policy is to reserve for uncollectible accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance for doubtful accounts is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Other factors that the Company considers include its existing contractual obligations, historical payment patterns of its customers and individual customer circumstances, an analysis of days sales outstanding by customer and geographic region, and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Account balances deemed to be uncollectible are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The allowance for doubtful accounts represents probable credit losses of $35,000 and $1,028,000 at December 31, 2020 and March 31, 2020, respectively. Additionally, at December 31, 2020 and March 31, 2020 the Company has allowances of $2,938,000 and $1,230,000, respectively, related to potential discounts, returns, distributor fees and rebates. The allowances are included in Accounts Receivable, net in the accompanying condensed consolidated balance sheets.
Inventories	Inventories Inventories are stated at the lower of cost, cost being determined on a standard cost basis (which approximates actual cost on a first-in, first-out basis), or net realizable value. Due to changing market conditions, estimated future requirements, age of the inventories on hand and production of new products, the Company regularly reviews inventory quantities on hand and records a provision to write down excess and obsolete inventory to its estimated net realizable value. The Company recorded a provision to reduce the carrying amounts of inventories to their net realizable value in the amount of $269,000 and $600,000 at December 31, 2020 and March 31, 2020, respectively, which is included in cost of product revenues on the Company’s accompanying condensed consolidated statements of comprehensive income (loss).
Subsequent Events	Subsequent Events Management has evaluated subsequent events or transactions occurring through the date the condensed consolidated financial statements were issued. (See Note 13)
Accounting Pronouncements Pending Adoption	Accounting Pronouncements Pending Adoption In December 2019, the FASB issued ASU No. 2019-12, Income Taxes: Simplifying the Accounting for Income Taxes (“Topic 740”), which simplifies the accounting for income taxes, eliminates certain exceptions within Topic 740 and clarifies certain other aspects of the current guidance to promote consistency among reporting entities. The new standard is effective for fiscal years beginning after December 15, 2020 on a prospective basis and early adoption is permitted. The Company is currently evaluating the impact of the provisions of this standard on its Consolidated Financial Statements.
Recent Accounting Standards	Recent Accounting Standards Accounting standards that have been issued or proposed by the FASB, the SEC or other standard setting bodies that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption.

3. Summary of Significant Acc_3

3. Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Computation of earnings per share	Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. Three Months Ended December 31, Nine Months Ended December 31, (In thousands, except per share data) 2020 2019 2020 2019 Numerator: Loss from continuing operations $ (626 ) $ (1,210 ) $ (1,183 ) $ (1,824 ) Income (loss) from discontinued operations (24 ) 126 893 252 Net loss $ (650 ) $ (1,084 ) $ (290 ) $ (1,572 ) Denominator: Weighted-average number of common shares outstanding: basic and diluted 2,052 1,500 1,967 1,378 Loss per share from continuing operations $ (0.31 ) $ (0.81 ) $ (0.60 ) $ (1.32 ) Income (loss) per share from discontinued operations (0.01 ) 0.09 0.45 0.18 Net loss per share: basic and diluted $ (0.32 ) $ (0.72 ) $ (0.15 ) $ (1.14 )
Schedule of antidilutive shares	The computation of basic loss per share for the three and nine months ended December 31, 2020 and 2019 excludes the potentially dilutive securities summarized in the table below because their inclusion would be anti-dilutive. Three Months Ended December 31, Nine Months Ended December 31, (In thousands) 2020 2019 2020 2019 Stock options 61 358 70 358 Restricted stock 1 2 1 2 Series C – 17 – 17 Warrants 119 468 119 468 Common stock units (1) 46 46 46 46 227 891 236 891 (1) Consists of 30,668 restricted stock units and warrants to purchase 15,332 shares of common stock
Disaggregated Revenue by Source	The following table presents the Company’s disaggregated revenues by revenue source: (In thousands) Three Months Ended December 31, Nine Months Ended December 31, Product 2020 2019 2020 2019 Human Care $ 3,534 $ 3,528 $ 13,628 $ 11,290 Animal Care 1,357 853 2,745 2,188 Other 45 14 99 138 $ 4,936 $ 4,395 $ 16,472 $ 13,616

4. Discontinued Operations_ S_2

4. Discontinued Operations: Sale of Assets to Infinity Labs SD, Inc. (Tables)	9 Months Ended
	Dec. 31, 2020
Discontinued Operations and Disposal Groups [Abstract]
Schedule of allocation of sale price	Proceeds were allocated to the components of the sale based upon their relative selling prices are as follows: Customer base $ 850,000 Less: Funds remaining in escrow (60,000 ) Less: Services due from buyer (100,000 ) Less: Working capital adjustment (80,000 ) Total proceeds $ 610,000
Assets and liabilities of disposal group	The carrying value of the assets and liabilities of discontinued operations on the condensed consolidated balance sheets as of December 31, 2020 and March 31, 2020 were as follows: December 31, 2020 March 31, 2020 Assets Accounts receivable (net) $ – $ 89,000 Inventory – 11,000 Operating lease, right of use – 604,000 Total current assets of discontinued operations $ – $ 704,000 Liabilities Accounts payable $ – $ 18,000 Operating lease – 117,000 Total current liabilities of discontinued operations $ – $ 135,000 Operating lease $ – $ 511,000 Total Long-term liabilities of discontinued operations $ – $ 511,000 The operations of the Micromed business included in discontinued operations is summarized as follows: Three Months Ended December 31, Nine Months Ended December 31, 2020 2019 2020 2019 Revenues $ – $ 283,000 $ 214,000 $ 741,000 Cost of revenues – 126,000 53,000 391,000 Selling general and administrative expenses (1,000 ) 31,000 38,000 98,000 Income (loss) from discontinued operations before tax 1,000 126,000 123,000 252,000 Gain (loss) on disposal of discontinued operations before income taxes (25,000 ) – 770,000 – Total income (loss) from discontinued operations, before tax (24,000 ) 126,000 893,000 252,000 Income Tax benefit (expense) – – – – Income (loss) from discontinued operations, net of tax $ (24,000 ) $ 126,000 $ 893,000 $ 252,000

5. Condensed Consolidated Bal_2

5. Condensed Consolidated Balance Sheets (Tables)	9 Months Ended
	Dec. 31, 2020
Disclosure Text Block Supplement [Abstract]
Schedule of inventories	Inventories, net consist of the following: December 31, March 31, 2020 2020 Raw materials $ 1,843,000 $ 1,128,000 Finished goods 1,115,000 1,064,000 $ 2,958,000 $ 2,192,000
Schedule of leases	The Company's operating leases are comprised primarily of operating facility leases. The Company did not have any finance leases as of December 31, 2020 and March 31, 2020. Balance sheet information related to our leases is presented below: December 31, March 31, 2020 2020 Operating leases: Operating lease right-of-use assets $ 671,000 $ 963,000 Operating lease liabilities – current 200,000 251,000 Operating lease liabilities – non-current 471,000 746,000
Schedule of annual minimum lease payments	As of December 31, 2020, the annual minimum lease payments of our operating lease liabilities were as follows: Three Months Ended December 31, Nine Months Ended December 31, 2020 2019 2020 2019 Operating Lease Costs $ 61,000 $ 146,000 $ 230,000 $ 444,000 Operating cash flows from operating leases 306,000 384,000 For Years Ending March 31, 2021 (excluding the nine months ended December 31, 2020) $ 56,000 2022 226,000 2023 183,000 2024 150,000 2025 104,000 Thereafter – Total future minimum lease payments, undiscounted 719,000 Less: imputed interest (48,000 ) Present value of future minimum lease payments $ 671,000 Weighted-average remaining lease term – operating leases (in months) 41 Weighted-average discount rate – operating leases 6.00%

9. Stock-Based Compensation (Ta

9. Stock-Based Compensation (Tables)	9 Months Ended
	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Share-based compensation expense	Stock-based compensation expense is as follows: Three Months Ended December 31, Nine Months Ended December 31, (In thousands) 2020 2019 2020 2019 Cost of revenues $ – $ 17 $ (27 ) $ 51 Research and development – 19 26 60 Selling, general and administrative 93 76 317 426 Total stock-based compensation $ 93 $ 112 $ 316 $ 537
Schedule of option activity	Stock options award activity is as follows: Number of Weighted- Weighted- Aggregate Outstanding at April 1, 2020 378,000 $ 26.55 – – Options granted – $ – – – Options exercised 79,451 $ 5.68 – $ 285,326 Options forfeited 113,798 $ 6.05 – – Options expired 23,866 $ 123.02 – – Outstanding at December 31, 2020 160,885 $ 37.03 7.47 $ 291,291 Exercisable at December 31, 2020 156,575 $ 37.74 7.44 $ 281,616
Restricted Stock Award Activity	Restricted stock award activity is as follows: Number of Shares Weighted Average Award Date Fair Value per Share Unvested restricted stock awards outstanding at April 1, 2020 1,666 $ 13.68 Restricted stock awards granted 5,695 4.79 Restricted stock awards vested (6,528 ) 5.92 Restricted stock awards forfeited – – Unvested restricted stock awards outstanding at December 31, 2020 833 $ 13.68

11. Segment and Geographic In_2

11. Segment and Geographic Information (Tables)	9 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Segment and Geographic Information	The following table shows the Company’s revenues by geographic region: Three Months Ended December 31, Nine Months Ended December 31, (In thousands) 2020 2019 2020 2019 United States $ 1,978 $ 2,059 $ 5,582 $ 6,753 Latin America 1,307 1,002 5,659 2,715 Europe and Rest of the World 1,651 1,334 5,231 4,148 Total $ 4,936 $ 4,395 $ 16,472 $ 13,616

1. Organization and Recent De_2

1. Organization and Recent Developments (Details Narrative)	3 Months Ended
	Jun. 19, 2019shares	Dec. 31, 2020shares	Mar. 31, 2020shares	Jun. 18, 2019shares
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Reverse stock split	Effective June 19, 2019, the Company effected a reverse stock split of its common stock, par value $0.0001 per share. Every nine shares of common stock were reclassified and combined into one share of common stock.
Common stock outstanding	1,328,891	2,079,059	1,777,483	11,972,328
Reverse stock split	.1111111111

2. Liquidity and Financial Co_2

2. Liquidity and Financial Condition (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
	Jun. 24, 2020	May 02, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2020
Net loss			$ (650,000)	$ (1,084,000)	$ (290,000)	$ (1,572,000)
Accumulated deficit			(172,536,000)		(172,536,000)		$ (172,246,000)
Working capital			$ 12,329,000		12,329,000		$ 7,518,000
Cash received from sale of Micromed					610,000
Proceeds from exercise of stock options					451,000
Proceeds from exercise of warrants					1,759,000
Asset Purchase Agreement [Member]
Aggregate sale price of Micromed division	$ 850,000
Cash received from sale of Micromed	610,000
Credit received for future testing services from sale of Micromed	100,000
Sale of assets, amount held in escrow	60,000
Accounts receivable remaining from sale of asset	$ 81,000
Paycheck Protection Program [Member] | States Bank in Atlanta [Member]
Proceeds from loan		$ 1,310,000			$ 1,310,000
Loan interest rate		1.00%			1.00%
Loan maturity date		Apr. 29, 2022			Apr. 29, 2022
Forgiveness of loan		$ 930,000

3. Summary of Significant Acc_4

3. Summary of Significant Accounting Policies (Details - Earnings per share) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Numerator:
Loss from continuing operations	$ (626)	$ (1,210)	$ (1,183)	$ (1,824)
Income (loss) from discontinued operations	(24)	126	893	252
Net loss	$ (650)	$ (1,084)	$ (290)	$ (1,572)
Denominator:
Weighted-average number of common shares outstanding: basic and diluted	2,052	1,500	1,967	1,378
Loss per share from continuing operations	$ (0.31)	$ (0.81)	$ (0.60)	$ (1.32)
Income (loss) per share from discontinued operations	(0.01)	0.09	0.45	0.18
Net loss per share: basic and diluted	$ (0.32)	$ (0.72)	$ (0.15)	$ (1.14)

3. Summary of Significant Acc_5

3. Summary of Significant Accounting Policies (Details - Antidilutive shares) - shares		3 Months Ended		9 Months Ended
		Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Antidilutive shares		227,000	891,000	236,000	891,000
Stock Options [Member]
Antidilutive shares		61,000	358,000	70,000	358,000
Restricted Stock [Member]
Antidilutive shares		1,000	2,000	1,000	2,000
Series C [Member]
Antidilutive shares		0	17,000	0	17,000
Warrants [Member]
Antidilutive shares		119,000	468,000	119,000	468,000
Common Stock Units [Member]
Antidilutive shares	[1]	46,000	46,000	46,000	46,000
[1]	Consists of 30,668 restricted stock units and warrants to purchase 15,332 shares of common stock

3. Summary of Significant Acc_6

3. Summary of Significant Accounting Policies (Details - Disaggregated Revenues) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Revenues	$ 4,936	$ 4,395	$ 16,472	$ 13,616
Human Care [Member]
Revenues	3,534	3,528	13,628	11,290
Animal Care [Member]
Revenues	1,357	853	2,745	2,188
Other Sales [Member]
Revenues	$ 45	$ 14	$ 99	$ 138

3. Summary of Significant Acc_7

3. Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Dec. 31, 2020	Mar. 31, 2020
Accounting Policies [Abstract]
Allowance for doubtful accounts	$ 35,000	$ 1,028,000
Allowance for potential discounts, returns, distributor fees and rebates	2,938,000	1,230,000
Inventory reserves	$ 269,000	$ 600,000

4. Discontinued Operations_ S_3

4. Discontinued Operations: Sale of Assets (Details - Allocation of sale price) - USD ($)	3 Months Ended	9 Months Ended
	Jun. 24, 2020	Dec. 31, 2020	Dec. 31, 2019
Proceeds from sale of business		$ 610,000	$ 0
Micromed Laboratories [Member]
Customer base	$ 850,000
Less: Funds remaining in escrow	(60,000)
Less: Services due from buyer	(100,000)
Less: Working capital adjustment	(80,000)
Proceeds from sale of business	$ 610,000

4. Discontinued Operations_ S_4

4. Discontinued Operations: Sale of Assets to Infinity Labs SD, Inc. (Details - Assets and Liabilities) - Micromed Laboratories [Member] - USD ($)	Dec. 31, 2020	Mar. 31, 2020
Assets
Accounts receivable (net)	$ 0	$ 89,000
Inventory	0	11,000
Operating lease, right of use	0	604,000
Total current assets of discontinued operations	0	704,000
Liabilities
Accounts payable	0	18,000
Operating lease	0	117,000
Total current liabilities of discontinued operations	0	135,000
Operating lease	0	511,000
Total Long-term liabilities of discontinued operations	$ 0	$ 511,000

4. Discontinued Operations_ S_5

4. Discontinued Operations: Sale of Assets to Infinity Labs SD, Inc. (Details - Discontinued Operations) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Income from discontinued operations, net of tax	$ (24,000)	$ 126,000	$ 893,000	$ 252,000
Micromed Laboratories [Member]
Revenues	0	283,000	214,000	741,000
Cost of Revenues	0	126,000	53,000	391,000
Selling, general and administrative expenses	(1,000)	31,000	38,000	98,000
Income from discontinued operations before tax	1,000	126,000	123,000	252,000
Gain (loss) on disposal of discontinued operations before income taxes	(25,000)	0	770,000	0
Total income from discontinued operations, before tax	(24,000)	126,000	893,000	252,000
Income Tax benefit (expense)	0	0	0	0
Income from discontinued operations, net of tax	$ (24,000)	$ 126,000	$ 893,000	$ 252,000

5. Condensed Consolidated Bal_3

5. Condensed Consolidated Balance Sheets (Details - Inventories) - USD ($)	Dec. 31, 2020	Mar. 31, 2020
Inventories Details
Raw materials, net	$ 1,843,000	$ 1,128,000
Finished goods, net	1,115,000	1,064,000
Inventories, net	$ 2,958,000	$ 2,192,000

5. Condensed Consolidated Bal_4

5. Condensed Consolidated Balance Sheets (Details - Operating lease information) - USD ($)	Dec. 31, 2020	Mar. 31, 2020
Inventory Disclosure [Abstract]
Operating lease right-of-use assets	$ 671,000	$ 963,000
Operating lease liabilities - current	200,000	251,000
Operating lease liabilities - non- current	$ 471,000	$ 746,000

5. Condensed Consolidated Bal_5

5. Condensed Consolidated Balance Sheets (Details - Other lease information) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Inventories Details
Operating lease cost	$ 61,000	$ 146,000	$ 230,000	$ 444,000
Operating cash flows from operating leases			$ 306,000	$ 384,000

5. Condensed Consolidated Bal_6

5. Condensed Consolidated Balance Sheets (Details - Minimum lease payments)	Dec. 31, 2020USD ($)
Inventory Disclosure [Abstract]
2021 (excluding the nine months ended December 31, 2020)	$ 56,000
2022	226,000
2023	183,000
2024	150,000
2025	104,000
Thereafter	0
Total future minimum lease payments, undiscounted	719,000
Less imputed interest	(48,000)
Present value of future minimum lease payments	$ 671,000
Weighted-average remaining lease term - operating leases (in months)	41 months
Weighted-average discount rate - operating leases	6.00%

5. Condensed Consolidated Bal_7

5. Condensed Consolidated Balance Sheets (Details Narrative) - USD ($)	Dec. 31, 2020	Mar. 31, 2020
Disclosure Text Block Supplement [Abstract]
Inventory reserved for obsolescence	$ 269,000	$ 600,000

6. Commitments and Contingenc_2

6. Commitments and Contingencies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Potential severerance payments	$ 250,000		$ 250,000
Trombly Business Law [Member]
Legal fees	$ 51,000	$ 84,000	$ 165,000	$ 220,000

7. Debt (Details Narrative)

7. Debt (Details Narrative) - Paycheck Protection Program [Member] - States Bank in Atlanta [Member] - USD ($)	1 Months Ended	9 Months Ended
	May 02, 2020	Dec. 31, 2020
Proceeds from loan	$ 1,310,000	$ 1,310,000
Interest rate	1.00%	1.00%
Debt maturity date	Apr. 29, 2022	Apr. 29, 2022

8. Stockholders' Equity (Detail

8. Stockholders' Equity (Details Narrative) - $ / shares	Dec. 31, 2020	Mar. 31, 2020
Common stock par value	$ .0001	$ 0.0001
Common stock, shares authorized	24,000,000	24,000,000
Convertible Preferred Stock [Member]
Preferred stock, shares authorized	714,286	714,286
Preferred stock par value	$ 0.0001	$ 0.0001

9. Stock-Based Compensation (De

9. Stock-Based Compensation (Details-Stock-based compensation) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Total stock-based compensation	$ 93	$ 112	$ 316	$ 537
Cost of revenues [Member]
Total stock-based compensation	0	17	(27)	51
Research and development [Member]
Total stock-based compensation	0	19	26	60
Selling, general and administrative [Member]
Total stock-based compensation	$ 93	$ 76	$ 317	$ 426

9. Stock-Based Compensation (_2

9. Stock-Based Compensation (Details-Option activity) - Stock Options [Member]	9 Months Ended
	Dec. 31, 2020USD ($)$ / sharesshares
Options
Outstanding at beginning of period | shares	378,000
Granted | shares	0
Exercised | shares	79,451
Forfeited | shares	113,798
Expired | shares	23,866
Outstanding at end of period | shares	160,885
Exercisable at end of period | shares	156,575
Weighted Average Exercise Price
Outstanding at beginning of period | $ / shares	$ 26.55
Granted | $ / shares	0
Exercised | $ / shares	5.68
Forfeited | $ / shares	6.05
Expired | $ / shares	123.02
Outstanding at end of period | $ / shares	37.03
Exercisable at end of period | $ / shares	$ 37.74
Weighted Average Contractual Term
Outstanding at end of period	7 years 5 months 20 days
Exercisable at end of period	7 years 5 months 9 days
Aggregate Intrinsic Value
Exercised | $	$ 285,326
Outstanding at end of period | $	291,291
Exercisable at end of period | $	$ 281,616

9. Stock-Based Compensation (_3

9. Stock-Based Compensation (Details-Restricted stock activity) - Restricted Stock [Member]	9 Months Ended
	Dec. 31, 2020$ / sharesshares
Restricted stock award activity
Unvested restricted stock awards, beginning balance | shares	1,666
Restricted stock awards granted | shares	5,695
Restricted stock awards vested | shares	(6,528)
Restricted stock awards forfeited | shares	0
Unvested restricted stock awards, ending balance | shares	833
Weighted average award date fair value per share, outstanding beginning balance | $ / shares	$ 13.68
Weighted average award date fair value per share, granted | $ / shares	4.79
Weighted average award date fair value per share, vested | $ / shares	5.92
Weighted average award date fair value per share, forfeited | $ / shares	0
Weighted average award date fair value per share, outstanding ending balance | $ / shares	$ 13.68

9. Stock-Based Compensation (_4

9. Stock-Based Compensation (Details Narrative)	9 Months Ended
	Dec. 31, 2020USD ($)$ / shares
Restricted Stock [Member]
Unrecognized compensation costs - Options	$ 2,007
Weighted average amortization period	2 months 27 days
Stock Options [Member]
Unrecognized compensation costs - Options	$ 8,168
Weighted average amortization period	8 months 19 days
Aggregate intrinsic value per share | $ / shares	$ 7.26

11. Segment and Geographic In_3

11. Segment and Geographic Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Revenues	$ 4,936	$ 4,395	$ 16,472	$ 13,616
Product [Member] | UNITED STATES
Revenues	1,978	2,059	5,582	6,753
Product [Member] | Latin America [Member]
Revenues	1,307	1,002	5,659	2,715
Product [Member] | Europe and Rest of the World [Member]
Revenues	$ 1,651	$ 1,334	$ 5,231	$ 4,148

12. Significant Customer Conc_2

12. Significant Customer Concentrations (Details Narrative)	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Revenues [Member] | One Customer [Member]
Concentration risk percentage	26.00%	21.00%	34.00%	18.00%
Revenues [Member] | Another Customer [Member]
Concentration risk percentage	24.00%		14.00%
Revenues [Member] | Two Customer [Member]
Concentration risk percentage		15.00%		12.00%
Accounts Receivable [Member]
Concentration risk percentage			10.00%
Accounts Receivable [Member] | One Customer [Member]
Concentration risk percentage			10.00%